Meeting
2023 ASCO Annual Meeting
Clinical practice guideline descriptions of oncologic drugs granted FDA accelerated approval: A cross-sectional study.
Authors
Maryam Mooghali
Yale School of Medicine, New Haven, CT
Maryam Mooghali , Joshua David Wallach , Aaron Philip Mitchell , Joshua J Skydel , Joseph S. Ross , Reshma Ramachandran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Health and Regulatory Policy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1590)
DOI
10.1200/JCO.2023.41.16_suppl.1590
Abstract #
1590
Poster Bd #
184
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of accelerated approval (AA) status with National Comprehensive Cancer Network (NCCN) guideline recommendation for cancer drug indications: A cross-sectional study.
First Author: Edward Robert Scheffer Cliff
First Author: Gargi D. Basu
Poster
2023 ASCO Quality Care Symposium
An innovative approach to “off pathway prescribing” to improve pathway adherence and practice collegiality utilizing a peer-reviewed process and scorecards.
First Author: Matthew Rama Skelton
Poster
2023 ASCO Annual Meeting
Data transparency and demographic representation in approval packages of FDA-approved oncology drugs from 2012-2021.
First Author: Jingyi Liu